Inositol administration reduces oxidative stress in erythrocytes of patients with polycystic ovary syndrome

Inositol administration reduces oxidative stress in erythrocytes
of patients with polycystic ovary syndrome

Gabriella Dona`, Chiara Sabbadin1, Cristina Fiore1, Marcantonio Bragadin2, Francesco L Giorgino3,
Eugenio Ragazzi4, Giulio Clari, Luciana Bordin* and Decio Armanini1,*
Department of Biological Chemistry, University of Padua, Viale G. Colombo 3, 35131 Padua, Italy, 1Endocrinology Unit, Department of Medical and
Surgical Sciences, University of Padua, Via Ospedale 105, 35128 Padua, Italy, 2Department of Environmental Sciences, University of Venice, Venice, Italy,
3Associazione Ginecologi Extra Ospedalieri (A.G.E.O.), Padua, Italy and 4Department of Pharmacology and Anesthesiology, University of Padua, Padua,
(Correspondence should be addressed to L Bordin; Email:; D Armanini; Email:
*(L Bordin and D Armanini contributed equally to this work)
Objective: Possibly due to a deficiency of insulin mediators, polycystic ovary syndrome (PCOS) is
often associated with insulin resistance (IR) and hyperinsulinemia, likely responsible for an elevated
production of reactive oxygen species. We investigated oxidative-related alterations in erythrocytes
and anti-inflammatory effects of inositol in women with PCOS before and after treatment with
myo-inositol (MYO).
Methods: Twenty-six normal-weight PCOS patients Q2 were investigated before and after MYO
administration (1200 mg/day for 12 weeks; nZ18) or placebo (nZ8) by evaluating serum
testosterone, serum androstenedione, fasting serum insulin, fasting serum glucose, insulin area
under the curve (AUC), and glucose AUC after oral glucose tolerance test and homeostasis model of
assessment–IR. In erythrocytes, band 3 tyrosine phosphorylation (Tyr-P) level, glutathione (GSH)
Q3 content, and glutathionylated proteins (GSSP) were also assessed.
Results: Data show that PCOS patients’ erythrocytes underwent oxidative stress as indicated by band 3
Tyr-P values, reduced cytosolic GSH content, and increased membrane protein glutathionylation.
MYO treatment significantly improved metabolic and biochemical parameters. Significant reductions
were found in IR and serum values of androstenedione and testosterone. A significant association
between band 3 Tyr-P levels and insulin AUC was found at baseline but disappeared after MYO
treatment, while a correlation between band 3 Tyr-P and testosterone levels was detected both before
and after MYO treatment.
Conclusions: PCOS patients suffer from a systemic inflammatory status that induces erythrocyte
membrane alterations. Treatment with MYO is effective in reducing hormonal, metabolic, and
oxidative abnormalities in PCOS patients by improving IR.


Comments are closed.